Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Polypeptide Laboratories (Sweden) AB
AB
Active
Org 5563897254
Högerudsgatan 21, 216 13
Limhamn
Manufacture of basic pharmaceutical products
·
NACE 2110
Est. 1990 · 36 years old
350 employees
Monitor
Share
Sweden
/
Companies
/
Manufacture of basic pharmaceutical products
/
Polypeptide Laboratories (Sweden) AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
1.5B
1.1B
0.7B
0.4B
0B
2020: 0.7B
0.7B
2020
2021: 1.0B (+33% vs 2020)
1.0B
+33%
2021
2022: 0.9B (-8% vs 2021)
0.9B
-8%
2022
2023: 1.1B (+18% vs 2022)
1.1B
+18%
2023
2024: 1.2B (+11% vs 2023)
1.2B
+11%
2024
EBITDA
SEK millions
484M
363M
242M
121M
0M
2020: 241M
241M
2020
2021: 389M (+61% vs 2020)
389M
+61%
2021
2022: 244M (-37% vs 2021)
244M
-37%
2022
2023: 212M (-13% vs 2022)
212M
-13%
2023
2024: 297M (+40% vs 2023)
297M
+40%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
1 179 387
1 066 269
901 324
977 189
732 030
Staff expenses
—
—
—
—
—
EBITDA
297 152
212 148
243 820
388 836
241 072
Depreciation & amort.
—
—
—
—
—
EBIT
297 152
212 148
243 820
388 836
241 072
Net financials
26 066
−32 024
55 813
19 069
−26 362
Profit before tax
15 460
1 516
66 336
295 769
153 853
Tax
−2 032
−647
−13 155
−57 490
−33 059
Net profit
13 428
869
53 181
238 279
120 794
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
2 642 137
1 991 348
1 517 046
1 435 808
1 107 484
Equity
651 156
937 728
936 859
883 678
645 399
Long-term debt
932 672
256 983
0
0
0
Short-term debt
602 758
417 197
314 789
338 711
280 739
Total debt
1 535 430
674 180
314 789
338 711
280 739
Financial ratios
5-year trend
EBITDA margin
25,2 %
This company
15,8 %
Market median
This company
Market median
59% above market
2020
2024
Equity ratio
24,6 %
This company
38,2 %
Market median
This company
Market median
36% below market
2020
2024
Return on equity
2,1 %
This company
18,4 %
Market median
This company
Market median
89% below market
2020
2024
Net profit margin
1,1 %
This company
8,1 %
Market median
This company
Market median
86% below market
2020
2024
Asset turnover
0,45×
This company
1,12×
Market median
This company
Market median
60% below market
2020
2024
Debt / equity
3,06×
This company
0,62×
Market median
This company
Market median
394% above market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Polypeptide Laboratories (Sweden) AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
